Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
11.54
-1.02 (-8.12%)
Feb 21, 2025, 4:00 PM EST - Market closed
Gyre Therapeutics Employees
Gyre Therapeutics had 593 employees as of December 31, 2023.
Employees
593
Change
n/a
Growth
n/a
Revenue / Employee
$177,121
Profits / Employee
-$149,784
Market Cap
990.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 593 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
GYRE News
- 3 months ago - Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis - GlobeNewsWire
- 5 months ago - Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference - GlobeNewsWire
- 6 months ago - Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Gyre Therapeutics to Present at Sidoti Virtual Investor Conference - GlobeNewsWire
- 8 months ago - Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia - GlobeNewsWire
- 8 months ago - Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology - GlobeNewsWire
- 9 months ago - Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension - GlobeNewsWire